<DOC>
	<DOCNO>NCT00941720</DOCNO>
	<brief_summary>RATIONALE : Giving high-dose chemotherapy autologous stem cell transplant stop growth cancer cell stop divide kill . An autologous stem cell transplant may able replace blood-forming cell destroy chemotherapy . PURPOSE : This phase II trial study well give busulfan together cyclophosphamide follow autologous stem cell transplant work treat patient multiple myeloma .</brief_summary>
	<brief_title>Busulfan , Cyclophosphamide , Autologous Stem Cell Transplant Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare relapse-free survival overall survival patient multiple myeloma treat IV busulfan vs historical control patient treat oral busulfan administer cyclophosphamide conditioning regimen prior autologous hematopoietic stem cell transplantation . Secondary - To compare pulmonary toxicity rate IV busulfan v oral busulfan administer cyclophosphamide conditioning regimen prior autologous hematopoietic stem cell transplantation . OUTLINE : Patients receive high-dose busulfan IV every 6 hour day -8 -4 high-dose cyclophosphamide IV 4 hour day -3 -2 . Patients undergo autologous hematopoietic stem cell transplantation day 0 . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients diagnosis plasma cell myeloma Patients cardiac ejection fraction &gt; = 45 % clearance Cleveland Clinic Faculty ( CCF ) cardiologist Patients diffusion capacity carbon monoxide ( DLCO ) &gt; = 45 % predict clearance CCF pulmonologist Patient previously harvest peripheral blood progenitor cell minimum 2 x 10^6 CD 34+ cells/kg harvest EXCLUSION CRITERIA : Patients receive total body irradiation Nonmyeloablative/reducedintensity conditioning Pregnant breast feeding patient Human immunodeficiency virus ( HIV ) positive Patients serum creatinine &gt; 2.0 Prior Hematopoietic Stem Cell ( HSC ) transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>